Therapeutic drug monitoring (TDM) of iv busulfan (Bu) in adults undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT) to better control the targeted exposure after a 3-day Bu-based myeloablative conditioning (MAC)

被引：0
|
作者：
Amin, A. [1 ]
Bourget, P. [1 ]
Gomez, A. [2 ]
Ader, F. [1 ]
Joly, A. -C. [3 ]
Mamez, A-C. [2 ]
Brissot, E. [2 ]
Baylatry, M. T. [3 ]
Mohty, M. [2 ]
Rubio, M. -T. [2 ]
机构：
[1] Univ Hosp Necker Enfants Malad, Dept Clin Pharm, Paris, France
[2] Univ Hosp St Antoine, Dept Hematol, Paris, France
[3] Univ Hosp St Antoine, Dept Clin Pharm, Paris, France
来源：
BONE MARROW TRANSPLANTATION | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P207
引用
收藏
页码：S221 / S221
页数：1
相关论文
共 9 条
  • [1] REITERATED THERAPEUTIC DRUG MONITORING (TDM) TO BETTER CONTROL TARGETED EXPOSURE TO IV BUSULFAN IN INFANTS AND OLDER CHILDREN UNDERGOING HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)
    Bourget, P.
    Neven, B.
    Amin, A.
    Chomton, M.
    Cros, G.
    Elkaim, E.
    Fremond, M. -L.
    Moshous, D.
    Touzot, F.
    Ader, F.
    Lalli, A.
    Petain, A.
    Nguyen, L.
    Blanche, S.
    HAEMATOLOGICA, 2015, 100 : 281 - 281
  • [2] Contribution of reiterated therapeutic drug monitoring (TDM) of iv busulfan dosing in infants and older children undergoing hematopoietic stem-cell transplantation (HSCT) to better control the targeted exposure to a major alkylating agent
    Bourget, P.
    Neven, B.
    Amin, A.
    Ader, F.
    Chomton, M.
    Cros, G.
    Fremond, M. -L
    Moshous, D.
    Touzot, F.
    Petain, A.
    Nguyen, L.
    Poinsignon, V.
    Paci, A.
    Blanche, S.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S462 - S462
  • [3] Reiterated Therapeutic Drug Monitoring (TDM) Dosing to Significantly Improve the Control of Exposure to IV Busulfan in Infants and Older Children Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)
    Amin, Alexandre
    Bourget, Philippe
    Neven, Benedicte
    Fremond, Marie-Louise
    Castelle, Martin
    Elkaim, Elodie
    Cros, Guilhem
    Moshous, Despina
    Touzot, Fabien
    Lalli, Alexandre
    Petain, Aurelie
    Nguyen, Laurent
    Blanche, Stephane
    BLOOD, 2015, 126 (23)
  • [4] Descriptive analysis of changing toxicity profiles for 30 and 100 day mortality after matched related donor (MRD) allogeneic (ALLO) hematopoietic stem cell transplantation (HSCT) using PO vs iv busulfan (BU) based conditioning regimens
    Gupta, S
    Cole, SW
    Salzman, DE
    Ashraf, K
    Aggarwal, C
    Vaughan, WP
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 30 - 30
  • [5] Busulfan Exposure Target Attainment in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: A Single Day Versus a Multiple Day Therapeutic Drug Monitoring Regimen
    Bognar, T.
    Bartelink, I. H.
    van der Elst, K. C. M.
    Kingma, J. S.
    Smeijsters, E. H.
    Lindemans, C. A.
    Egberts, A. C. G.
    Kuball, J. H. E.
    de Witte, M. A.
    Schultink, A. H. M. de Vries
    Lalmohamed, A.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (10): : 1007e1 - 1007e10
  • [6] Implementation of Therapeutic Drug Monitoring (TDM) of piperacillin/tazobactam for patients with neutropenic fever after allogeneic hematopoietic stem cell transplantation (allo - HSCT) - a retrospective single-center observational study
    Kraus, S.
    Rauen, P.
    Zovko, J.
    Einsele, H.
    Surat, G.
    Steinbrunn, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 71 - 71
  • [7] Intravenous Busulfan (IV Bu)-Based Conditioning Regimen Before Allogeneic Stem Cell Transplantation (allo-SCT) for Adults with Acute Lymphoid Leukemia (ALL): A Aurvey From the Acute Leukemia Working Party of EBMT
    Mohty, Mohamad
    Labopin, Myriam
    Sanz, Miguel A.
    Hamljadi, Rose-Marie
    Koza, Vladimir
    Arcese, William
    Campos, Antonio
    Milpied, Noel-Jean
    Nagler, Arnon
    BLOOD, 2011, 118 (21) : 1294 - 1294
  • [8] TWICE-DAILY INTRAVENOUS (IV) BUSULFAN (Bu) X 4 DAYS IN CHILDREN UNDERGOING A REDUCED-INTENSITY CONDITIONING (RIC) REGIMEN WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AlloHSCT) IS SAFE AND WELL-TOLERATED BUT RESULTS IN SIGNIFICANTLY INCREASED Bu CLEARANCE (CL) AND DECREASED AREA UNDER THE CURVE (AUC) AND HALF-LIFE (t1/2) WHEN COMPARED TO IV BU TWICE-DAILY DOSING PHARMACOKINETICS (PK) IN ADULTS
    Waxman, I
    Bhatia, M.
    Milone, M.
    Shaw, L. M.
    Baldinger, L.
    Militano, O.
    Garvin, J.
    George, D.
    Bradley, M. B.
    Satwani, P.
    Schwartz, J.
    Wolownik, K.
    Foley, S.
    Hawks, R.
    Jin, Z. Z.
    Baxter-Lowe, L. A.
    van de Ven, C.
    Cairo, M. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 85 - 85
  • [9] Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT
    Mohty, Mohamad
    Labopin, Myriam
    Socie, Gerard
    Milpied, Noel-Jean
    Attal, Michel
    Blaise, Didier
    Ringden, Olle
    Brown, Paul
    Lorentz, Brinch
    Brune, Mats L.
    Hamladji, Rose-Marie
    Duarte, Rafael F.
    Nagler, Arnon
    Rocha, Vanderson
    BLOOD, 2009, 114 (22) : 1306 - 1306
1